Anika Therapeutics Inc (NAS:ANIK)
$ 17.35 -0.2 (-1.14%) Market Cap: 254.10 Mil Enterprise Value: 219.27 Mil PE Ratio: 0 PB Ratio: 1.42 GF Score: 70/100

Q4 2020 Anika Therapeutics Inc Earnings Call Transcript

Mar 04, 2021 / 10:00PM GMT
Release Date Price: $38.13 (-1.47%)
Operator

Good evening, ladies and gentlemen, and welcome to Anika's Fourth Quarter and Full Year 2020 Earnings Conference Call. (Operator Instructions) The conference is being recorded. (Operator Instructions)

I will now turn the call over to Mark Namaroff, Executive Director of Investor Relations and Corporate Communications. Please go ahead.

Mark Namaroff
Anika Therapeutics, Inc. - Executive Director of IR & Corporate Communications

Thank you, Therese. Good evening, everyone. And thank you for joining us for Anika's fourth quarter and year-end conference call and webcast. Our Q4 and year-end earnings press release was issued after the close of the market today and is available on our Investor Relations website located at www.anika.com as well as the supplementary PowerPoint slides that will be used for the discussion today.

So with me on the call today is Dr. Cheryl Blanchard, President and Chief Executive Officer; and Mike Levitz, Executive Vice President, Chief Financial Officer

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot